DxS
-
Qiagen Acquires License for Key PI3K Gene
Qiagen has announced that its wholly owned subsidiary DxS has acquired the global and exclusive license for biomarker PI3K from Johns Hopkins University, to develop real-time Polymerase Chain Reaction (RT-PCR) and endpoint PCR assays. Research has sh…
DxS | 26 February 2010
-
Qiagen and Pfizer to Develop Diagnostic for Brain Tumor Vaccine
Pfizer and DxS (a wholly owned subsidiary of Qiagen) have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110) – an immunotherapy vaccine in development for the treatment of Glioblastoma Multiforme (GBM). F…
DxS | 18 February 2010
-
Qiagen Acquires DxS
Qiagen has acquired DxS, a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, UK. The transaction is valued at approximately US$95 million in cash, plus up to an additional US$35 million if specifi…
DxS | 09 October 2009
